Research and Policy CSR News

The CEO Investor Forum Launches Partnership with the Biopharma Sustainability Roundtable to Address the Need for Stronger Industry-wide Sustainability Efforts in Biotech and Pharmaceuticals Sector

Press Release

NEW YORK, July 9,2020 /3BL Media/ — Pharmaceutical and biotech companies are actively working to enhance their sustainability efforts to increase the emphasis on long-term value creation, stakeholder engagement, and forward-looking disclosures. To support these efforts, the Biopharma Sustainability Roundtable (BSRT) has formed a partnership with CECP’s CEO Investor Forum. Together, the two groups will co-host the first sector-specific CEO-Investor Forum in June 2021.

5 Latest Facts About Johnson & Johnson's Ebola Vaccine

As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
Blog

One of the world's deadliest viral diseases was discovered in 1976 in Zaire, now known as the Democratic Republic of the Congo (DRC), near the Ebola River.

Since then, there have been 30 outbreaks of Ebola Virus Disease (EVD)—the worst of which hit in West Africa in 2014. During that two-year epidemic, more than 11,000 people died in Guinea, Liberia and Sierra Leone. Two in five individuals who were infected with the disease, then lost their lives.

"AIDS Won't Stop for COVID-19": Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History

Summary: 

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Blog

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Increasing Diversity in Clinical Trials: A Collaboration with Tufts Center for the Study of Drug Development

Article

To effectively support the goal of access for all citizens, we must consider all citizens. But delivering on that goal takes a commitment to understanding deeply who patients are, their needs, and how we can best support positive health outcomes. We need to start at the beginning and build into every decision we make and step we take the diverse socio economic and individual health considerations of each person we encounter.

Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine

Summary: 
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19
Press Release
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19

Following Emergency Pandemic Response, the Tomorrow Rising Fund by the Schneider Electric Foundation Focuses Support on Recovery and Resiliency

Summary: 
  • Schneider Electric Foundation launched the Tomorrow Rising Fund to help vulnerable communities respond, recover and become more resilient in the wake of Covid-19
  • Schneider Electric’s people and partners across +60 countries have joined in by fundraising and volunteering to contribute to 65 projects which benefit +800,000 people
  • Following the initial emergency response, the fund continues to support education and professional training to secure the best future for young people and their communities
Press Release
  • Schneider Electric Foundation launched the Tomorrow Rising Fund to help vulnerable communities respond, recover and become more resilient in the wake of Covid-19
  • Schneider Electric’s people and partners across +60 countries have joined in by fundraising and volunteering to contribute to 65 projects which benefit +800,000 people
  • Following the initial emergency response, the fund continues to support education and professional training to secure the best future for young people and their communities

Behind Every Rapid Response Is a Strong Regulatory Strategy

by Christa Myers, Process Engineer, and Marc Pelletier, PhD, Process Specialist
Blog

During a global pandemic, the pharmaceutical industry must juggle the need for speed and the need to protect patient safety. A strong regulatory strategy makes it possible to accelerate drug development without getting slowed down by compliance considerations. 

In Praise of Paper Ballots

Blog

As we enter into the 2020 election season, the way in which we participate has the potential to be impacted. From concerns around vote hacking to the fear of exposure to COVID-19, states are under increased scrutiny about how they will handle this year’s election. There is one thing that provides a good solution for both concerns – paper.

The Security of Paper Ballots

An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences

Blog

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.

Cancer Immunotherapy Awareness Month™ at Alkermes

Multimedia with summary

Along with the Society for Immunotherapy of Cancer we strive for a future #Immune2Cancer because to our team, cancer immunotherapy research is personal. Our scientists are researching potential, new cancer treatment options for our loved ones and yours.

About Alkermes

Pages

Subscribe to Research and Policy